Coronavirus | Sputnik V vaccine yet to receive SEC approval for emergency use

The Subject Expert Committee has sought additional data.

April 01, 2021 08:15 pm | Updated 09:00 pm IST - NEW DELHI

Vials of the Sputnik V COVID-19 vaccine.

Vials of the Sputnik V COVID-19 vaccine.

Sputnik V vaccine has not got the emergency use authorisation on Thursday, confirmed an official, following the meeting of the Subject Expert Committee (SEC). The Committee, set up by the government, looked into Dr Reddy’s application seeking the approval for the vaccine use in India.

While additional data has been sought by SEC, the approval would have made Sputnik V the third vaccine to be administered in India against coronavirus.

Dr Reddy's Lab has partnered with the Russia Direct Investment Fund (RDIF) to bring the Sputnik V vaccine to India and other countries. The panel had last month sought immunogenicity data. Sputnik V is a two dose vaccine, with the claim of 91.6% efficacy against SARS-CoV-2.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.